Pharvaris NV opened lower at $33.59, compared with its previous close of $34.18. In the last trading session, the stock traded between $33.00 and $34.55. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Pharvaris NV is now worth
$ 211.73
Giving a profit of
$ 111.73 (111.73%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 12 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.30 (-0.89%)
Day High
$34.55
Day Low
$33.00
Day Open
$33.59
Prev Close
$34.18
Volume
3,12,218
1W Return
-1.35%
1M Return
9.74%
3M Return
-1.34%
6M Return
13.11%
1Y Return
40.45%
Fundamentals
Market Cap ($ Mn)
2,367
PE Ratio
-
PB Ratio
7.23
PEG Ratio
-
ROE
-69.67%
ROCE
-71.32%
EPS (TTM)
$-0.68
Investment Returns
1 Week
-1.35%
1 Month
9.74%
3 Months
-1.34%
6 Months
13.11%
9 Months
24.05%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
Updates
12Nov
Pharvaris ends Q3 with €283M cash, loss per share widens 11.7%
Pharvaris NV reported a Q3 loss per share of €(0.67). The loss widened 11.7% YoY from €(0.60) in the prior year. The company ended the quarter with €283 million in cash.
Today
29Oct
Pharvaris to present Phase 3 deucrictibant data at ACAAI 2026
Pharvaris presents one oral and five poster abstracts at ACAAI 2026 in Phoenix. Pivotal Phase 3 CHAPTER-3 study on deucrictibant ER tablet featured in oral session. Data covers efficacy, cardiovascular safety, and economic burden of HAE treatment. Presentations scheduled between November 12 and 16, 2026.
14 days ago
23Oct
B of A Securities upgrades Pharvaris to Buy, keeps $44 price target
B of A Securities upgraded Pharvaris from Neutral to Buy. Price target maintained at $44 per share. Analyst Tazeen Ahmad issued the rating change.
20 days ago
9Oct
Pharvaris Lancet data shows HAE relief in 1.28 hours
Deucrictibant IR achieved symptom relief in 1.28 hours and complete resolution in 11.95 hours. Study met primary endpoint and all 11 secondary endpoints with high statistical significance. Drug showed well-tolerated safety profile with no safety signals observed. NDA under FDA review with PDUFA date April 23, 2027; MAA under EMA review.
1mo ago
3Sep
Pharvaris presents deucrictibant Phase 3 and long-term safety data
Phase 3 RAPIDe-3 trial shows median time to symptom relief of 1.20 hours in North America. Long-term prophylaxis reduces mean attack rate from 2.18 to 0.12 per month over 22.2 months. Median time to End of Progression is 17.5 minutes versus 228.7 minutes for placebo. No serious treatment-related adverse events or cardiovascular safety signals observed. Safety margins established for combined use of 40mg XR tablet and 20mg IR capsule.
2mo ago
12Aug
Pharvaris Q2 EPS of $(0.81) misses $(0.74) analyst estimate
Pharvaris missed Q2 EPS estimates with a loss of $(0.81) per share versus $(0.74) expected, driven by higher R&D and G&A expenses. Despite the miss, the company maintains a strong cash position of €318 million following a $132 million equity raise.
